ICML 2017 | A novel WINDOW of opportunity for young mantle cell lymphoma patients
Michael Wang
• 14 Jun 2017
Michael Wang, MD from the MD Anderson Cancer Center, Houston, TX discusses the results from the successful WINDOW study (NCT02427620), presented at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Prof. Wang explains the study design, which saw young, newly diagnosed mantle cell lymphoma patients receive a combination of ibrutinib and rituximab followed by reduced chemo-immunotherapy. This combination of targeted therapy achieved a response in 100% of patients and complete remission in 90%. By reducing the need for chemotherapy, treatment associated toxicities can be decreased thus giving this subset of patients a better quality of life.
